What If PTSD Treatment Does Not Work? Reassessment and Next Steps
Author: Ukrainian Psychological Hub · Published: October 9, 2026 · Editorial Policy
When treatment for posttraumatic stress disorder (PTSD) is not helping enough, the next step is a structured review with a qualified clinician. The review should examine what has actually changed, whether the diagnosis and treatment targets are accurate, whether an adequate course of an evidence-based intervention was delivered, and which obstacles or additional conditions need attention. Depending on those findings, reasonable options include adapting the current treatment, completing an interrupted course, choosing another evidence-based trauma-focused psychotherapy, considering an appropriate medication, or arranging a specialist assessment. An ineffective first treatment is information that can guide better care.
This article addresses a specific clinical question: what to do when PTSD treatment produces little improvement, only partial improvement, a relapse, intolerable adverse effects, or a treatment experience that feels impossible to continue. It focuses primarily on adult care. The approach draws on the 2023 VA/DoD guideline, the 2025 American Psychological Association guideline, and NICE guideline NG116, which explicitly calls for further assessment and support when PTSD treatment has not provided sufficient benefit.
I. Can PTSD Treatment Fail Even When It Is Evidence-Based?
Yes. Evidence-based treatment increases the probability of improvement across research populations; it cannot predict the outcome of every individual course. In a 2024 meta-analysis of 86 randomized studies involving 7,894 participants, Semmlinger and colleagues estimated a weighted mean nonresponse rate of 39.23% after guideline-recommended psychological treatments. This figure describes the studies' particular definitions of nonresponse and their populations. It does not mean 39% of all people with PTSD are permanently unable to recover. There was substantial between-study heterogeneity, and half the studies were judged to have high risk of bias.
Treatment results also depend on which outcome is measured. Someone may experience fewer nightmares yet continue avoiding important places; another person may improve on a symptom scale but remain unable to return to work; someone else may have meaningful gains and continue to meet diagnostic criteria. Research averages cannot replace an assessment of symptom change, functioning, safety, and the person's goals. The VA National Center for PTSD emphasizes shared treatment decisions because no current method can reliably identify in advance which recommended treatment will work best for a particular person.
1. Nonresponse, partial response, remission, and relapse
Nonresponse usually means the intervention has produced little or no clinically meaningful improvement according to a stated measure and time point. Partial response means measurable gains have occurred, but important symptoms or difficulties remain. Remission means symptoms have fallen below a specified clinical threshold, although definitions differ across studies and instruments. Relapse refers to a return or worsening of symptoms after an initial improvement. Dropout means a person stops attending or stops participating before an intended endpoint; it is neither proof of treatment failure nor proof of successful recovery.
These distinctions matter because each leads to a different review. A person who never received a structured PTSD intervention needs a different plan from someone who completed a well-delivered course of cognitive processing therapy and still has severe intrusive memories. A person whose PTSD improved but whose insomnia persists may need targeted sleep care rather than another full course focused on trauma memory.
2. Why a difficult session does not by itself mean treatment is failing
Trauma-focused treatment may temporarily increase distress while sensitive material is discussed or approached. A temporary increase in emotion during or after a session does not, by itself, establish harm or predict the final outcome. Equally, prolonged deterioration, unsafe symptoms, intolerable distress, or worsening functioning deserve prompt attention. The correct clinical question is whether the treatment remains safe, tolerable, relevant to the agreed goals, and accompanied by meaningful progress over an appropriate interval. Clinicians should explain the expected process and adjust the plan when the actual pattern diverges from expectations.
II. First Determine What Has and Has Not Improved
A treatment review begins with a timeline: symptom severity and functioning before treatment, at several points during care, and at the present assessment. It records the specific intervention received, the number and timing of sessions, treatment interruptions, changes in medication, major life events, and any new safety concerns. When possible, use the same validated measure across assessments and discuss change alongside lived experience.
The PTSD Checklist for DSM-5 (PCL-5) is a 20-item self-report measure used for screening and monitoring. The VA notes that a reduction of approximately 10 points has been suggested as an indicator of response, while also emphasizing limits in the evidence for clinically meaningful change. A score, change score, or cut point is never a standalone diagnosis. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is a structured interview used by trained clinicians for diagnostic assessment and severity evaluation.
3. Measure outcomes that matter beyond a questionnaire
Review intrusive memories, nightmares, avoidance, hypervigilance, trauma-related beliefs, mood, dissociation, sleep, substance use, and physical symptoms. Then examine work or school attendance, ability to leave home, relationships, daily activities, independence, and quality of life. Some changes are gradual or uneven. Meaningful changes may include returning to a previously avoided activity, sleeping more consistently, using fewer emergency services, or tolerating reminders with less disruption, even while symptoms remain.
A good progress review documents both improvement and continuing difficulties. Patients can ask which symptoms are the principal targets, how progress will be measured, when the plan will be reviewed, and what constitutes a reason to change course. A clinician should also ask whether the chosen goals reflect the patient's own priorities.
4. When should a treatment plan be reviewed?
There is no universal number of sessions after which every PTSD therapy must be declared unsuccessful. The relevant interval depends on the specific protocol, session frequency, whether the intervention has reached its active treatment components, the severity of symptoms, and the person's circumstances. NICE describes trauma-focused CBT commonly delivered over 8–12 sessions, with additional sessions when clinically indicated, and similar flexibility for EMDR. Other protocols differ. It is reasonable to request a progress conversation at any point, including early in treatment, and especially when symptoms worsen, appointments become hard to attend, or the patient no longer understands the treatment plan.
III. Reassess the Diagnosis and the Problems Being Treated
A fresh clinical formulation asks whether the original PTSD diagnosis fits the present picture and whether important co-occurring problems have been missed. PTSD is a diagnostic disorder established through symptom criteria, relevant exposure, duration, impairment, and differential assessment. Traumatic exposure itself, acute stress reactions, acute stress disorder, persistent trauma-related symptoms, and positive screening questionnaires are different clinical concepts.
DSM-5-TR PTSD and ICD-11 PTSD do not use identical symptom groupings. ICD-11 also recognizes complex PTSD, which adds disturbances in self-organization involving emotional regulation, self-concept, and relationships. Complex PTSD is not a separate DSM-5-TR diagnosis. The DSM PTSD dissociative subtype concerns prominent depersonalization or derealization, while independent dissociative disorders require their own assessments. The VA review of ICD-11 complex PTSD assessment and treatment describes the International Trauma Questionnaire as a provisional self-report assessment rather than a substitute for clinician evaluation.
5. Common alternative or co-occurring explanations
Depression may account for persistent low mood, loss of pleasure, suicidal thinking, or fatigue. Obsessive-compulsive disorder can involve intrusive thoughts and avoidance that superficially resemble trauma reminders but differ in meaning and the function of rituals. Panic disorder and generalized anxiety disorder can contribute fear, anticipatory anxiety, and physiological arousal. Substance use may complicate sleep, mood, treatment engagement, and safety. Bipolar disorder, psychotic symptoms, neurological conditions, traumatic brain injury, medication effects, chronic pain, and sleep disorders can require separate assessment or coordinated management.
Clinicians should ask whether someone is still exposed to violence, threats, housing insecurity, discrimination, ongoing legal stress, or other conditions that maintain danger and impair access to care. These real-world circumstances can change what treatment is feasible and urgent. Clinical reassessment should make room for culture, language, developmental history, disability, and the person's preferred explanation of their difficulties. NICE NG116 recommends a comprehensive evaluation of physical, psychological, social, and safety needs.
6. PTSD with complex features, dissociation, or multiple traumatic experiences
Additional emotion-regulation and relationship difficulties can complicate engagement, but do not establish that a person is incapable of trauma-focused treatment. The evidence does not justify requiring every person with complex PTSD to complete a lengthy preparatory phase before any trauma-focused work. The VA clinical evidence review describes trials in which phase-based approaches were not clearly superior to standard trauma-focused interventions and notes that specifically ICD-11-defined complex PTSD treatment trials remain limited. A clinician may tailor pacing, alliance-building, skills support, and treatment targets according to actual needs.
IV. Was an Adequate PTSD Treatment Actually Delivered?
The name of a therapy is less informative than its content. General counseling, supportive conversation, stress-management advice, or a few sessions addressing everyday difficulties may be helpful without constituting a completed course of a recommended PTSD-specific treatment. A review should identify the protocol, its active components, the clinician's training and supervision, the treatment dose, and the barriers that prevented delivery.
The VA/DoD recommendations place individual trauma-focused psychotherapy—particularly prolonged exposure (PE), cognitive processing therapy (CPT), and eye movement desensitization and reprocessing (EMDR)—at the center of adult PTSD care. The APA 2025 guideline also prioritizes established cognitive-behavioral approaches, with varying recommendation strengths for specific interventions and medications. The guidelines differ in their evidence-grading systems and should be read on their own terms.
7. Check treatment delivery without blaming the patient
Useful review questions include whether appointments were accessible, whether the therapy's proposed mechanism was explained, whether the patient consented to its methods, whether homework or between-session work was appropriate and manageable, and whether cultural or language barriers interfered. Practical problems—cost, unstable transportation, caregiving, fatigue, disability, and lack of privacy—can disrupt a course even when the treatment itself is well chosen. The response is to identify feasible adaptations, additional support, a different setting, or another qualified clinician, rather than assuming the person simply lacked motivation.
8. What if a therapist and patient cannot agree on the approach?
Treatment preference and therapeutic alliance matter to engagement. A patient may request an explanation, collaborative revision, professional consultation, or a second opinion. The aim is a clear review of fit, risks, alternatives, and continuity of care. Abruptly discontinuing an essential medication or losing access to crisis support can create additional problems, so planned transitions are preferable wherever possible.
V. Evidence-Based Options After Limited Improvement
There is no single validated sequence that tells every person to move automatically from one PTSD intervention to another. After reassessment, the clinician and patient choose among evidence-supported treatments while taking account of prior exposure to each approach, response, tolerability, comorbidity, access, and preferences. Research on initial PTSD treatment efficacy is considerably stronger than research directly comparing exact second-line sequences after a clearly defined treatment failure.
9. Continue or adapt a partly effective treatment
If a person has begun to improve, the team may examine whether completing the protocol, extending treatment when clinically justified, revisiting a specific obstacle, or scheduling follow-up sessions is reasonable. More sessions are not automatically better; additional treatment should have a documented rationale and measurable goals. NICE allows extra trauma-focused sessions for people with multiple traumatic experiences and highlights ongoing support for residual symptoms. Persistent sleep disturbance, anger, or other specific symptoms may be addressed with targeted interventions, particularly when trauma-focused treatment has been completed or cannot currently be undertaken.
10. Consider another evidence-based trauma-focused therapy
Cognitive processing therapy addresses trauma-related interpretations and beliefs, including guilt, blame, danger, and trust. Prolonged exposure involves carefully planned, clinician-guided work with trauma memories and safely approachable reminders to reduce avoidance and facilitate learning. EMDR uses a structured protocol that includes work with trauma memories and bilateral stimulation. These methods have distinct procedures and active ingredients, and a poor response to one does not prove that the others will be ineffective. Their effectiveness is established primarily as initial PTSD treatments; evidence for a specific switch after nonresponse is less developed.
Readers can compare our separate guides to cognitive processing therapy, prolonged exposure therapy, and EMDR for PTSD. Repeatedly revisiting a traumatic memory alone or attempting an intense self-directed exposure program is not a universal response to failed treatment. The appropriate procedure is selected and monitored by a trained clinician.
11. Consider PTSD medication, or reassess an existing prescription
When trauma-focused psychotherapy is unavailable, unacceptable, or insufficient for the person's circumstances, medication can be considered through shared decision-making. The 2023 VA/DoD guidance supports sertraline, paroxetine, and venlafaxine as medications with the most persuasive evidence for primary PTSD treatment; the APA guideline additionally conditionally suggests fluoxetine, illustrating differences between recommendation systems. In the United States, sertraline and paroxetine have FDA approval for PTSD. A prescriber should review actual use, adequate duration, tolerability, adverse effects, possible drug interactions, medical factors, and the intended treatment target before deciding on any change.
A clinician may discuss switching a medication, pursuing psychotherapy, or addressing a co-occurring disorder according to the full clinical picture. The VA/DoD evidence review found insufficient evidence to recommend routinely combining medication with psychotherapy to improve PTSD outcomes over the recommended therapies alone. That is a statement about the available PTSD-specific evidence, not a prohibition on treating co-occurring depression or another condition when indicated. Medication changes, especially antidepressant discontinuation, should be supervised rather than performed abruptly.
12. Treat persistent nightmares, insomnia, pain, or depression as identifiable targets
Once PTSD symptoms have been assessed, persistent problems can merit their own evidence-based treatment. Prazosin may be considered for PTSD-associated nightmares under the VA/DoD recommendations; the same guideline does not recommend prazosin for global PTSD symptoms. Chronic insomnia may warrant an appropriate behavioral sleep intervention. Chronic pain, substance use disorders, and depression may need coordinated care. This targeted strategy is especially useful when a person has achieved substantial PTSD symptom improvement but still experiences an important impairment. See our separately published guide to PTSD medications for evidence, risks, and decision-making.
13. Consider accessible and appropriately supported delivery formats
Video-based individual therapy can overcome transportation, geography, disability, or scheduling obstacles while maintaining access to trained clinicians. Evidence and guidelines support certain clinician-delivered remote PTSD treatments, although privacy, technology, safety planning, and the therapeutic setting must be considered. NICE also allows appropriately supported computerized trauma-focused CBT for selected adults, with restrictions relating to severity, significant dissociation, and risk of harm. A general-purpose chatbot, an unregulated AI companion, an unsupported exposure app, and a clinically evaluated PTSD program are different interventions. Results from one class should not be transferred to another.
14. Specialist consultation and higher levels of care
A specialist review may be appropriate when the diagnosis is uncertain, severe impairment persists after an adequate course, complex comorbidities are present, adverse medication effects are difficult to manage, or risk is increasing. Depending on local services, options may include a trauma specialist, a multidisciplinary team, coordinated mental health and addiction care, or more intensive treatment. Higher intensity is a clinical service decision based on assessed need and safety; it is not a universal indication for long-standing PTSD.
VI. Treatments to Approach With Particular Caution
Persistent symptoms can make dramatic claims of a guaranteed cure attractive. Strong clinical recommendations require convincing evidence of benefits and harms, quality-controlled delivery, and relevance to the person's condition. VA/DoD recommends against benzodiazepines for PTSD because evidence of enduring PTSD benefit is lacking and risks include dependence and cognitive harms. The guideline also recommends against cannabis or cannabis derivatives as PTSD treatment. A person already taking a benzodiazepine should discuss a supervised plan with the prescriber rather than stopping suddenly.
Other interventions, such as ketamine, MDMA-assisted therapy, neuromodulation protocols, or body-oriented methods, have differing and developing evidence bases, regulatory status, and safety profiles. Some are studied in clinical trials, but their existence does not make them established substitutes for recommended PTSD treatments. The 2023 VA/DoD medication guidance distinguishes recommendations against specific uses from insufficient evidence for others. Likewise, grounding, yoga, mindfulness, exercise, peer support, and social connection can support wellbeing or symptom management without being equivalent to a first-line treatment for PTSD itself.
A personalized plan should never depend on unsupported promises that trauma is literally stored in a body part, that all patients must recover through identical stages, or that emotional catharsis alone reliably resolves PTSD. These phrases may describe personal experience, but they do not establish a diagnostic mechanism or a proven treatment sequence.
VII. Why Some People Stop Treatment Before They Benefit
Failure to complete a course is clinically important but requires interpretation. In a 2024 individual-participant meta-analysis, Wright and colleagues analyzed available data from 25 trials of in-person trauma-focused CBT; 27% of the 823 participants did not complete the study's post-treatment assessment. Dropout was higher among military/veteran participants than civilian participants in the available sample. However, dropout in this analysis was defined through missing post-treatment assessment, so it does not perfectly capture a person's actual therapy experience, and data were unavailable from many eligible studies.
Practical access, cultural fit, shame, mistrust, treatment expectations, symptoms of avoidance, scheduling barriers, clinical side effects, and the clinician-patient relationship may all be relevant for an individual. Their relative importance should be established through discussion rather than assumed from group statistics. Clinicians can respond with clear communication, flexibility, safety planning, and choice. NICE specifically calls for engagement strategies and support when patients miss appointments.
VIII. What If Symptoms Get Worse During Treatment?
A short-lived increase in distress may occur during emotionally demanding therapy, but clinicians should actively investigate a sustained deterioration or a new danger. It is important to distinguish transient distress, symptom fluctuation, medication adverse effects, new trauma exposure, worsening depression, new suicidal thoughts, emerging mania or psychosis, substance withdrawal, and medical problems. The appropriate response depends on the actual cause and urgency.
15. When to contact the treating clinician promptly
Arrange a timely review when sleep collapses, panic or dissociation significantly increases, intrusive memories interfere more with daily functioning, adverse drug effects become hard to tolerate, substance use escalates, or the patient feels unable to continue sessions safely. Discuss what happened, any changes in medication or exposure, current supports, and whether the treatment plan needs alteration. Clinicians may adjust pacing, strengthen coping and safety supports, review medications, evaluate additional diagnoses, or revise the approach.
16. When urgent help is needed
If someone has immediate intent to harm themselves or another person, cannot maintain safety, develops severe confusion or psychotic symptoms, or has a serious medical reaction, seek urgent local emergency or crisis services. In the United States, call or text 988 for the Suicide & Crisis Lifeline, or contact emergency services for immediate danger. Elsewhere, use local emergency and crisis services. A crisis response addresses immediate safety, followed by continuity of PTSD care after stabilization.
IX. Special Clinical Situations
17. Complex PTSD and persistent interpersonal difficulties
The ICD-11 complex PTSD framework includes PTSD symptoms together with sustained disturbances in emotion regulation, self-concept, and relationships. These difficulties may need a flexible plan with attention to trust, stabilization where clinically useful, and interpersonal support. The limited head-to-head evidence does not establish that every patient must complete a universal sequence of separate stages. Our complex PTSD treatment guide addresses the specific treatments and evidence.
18. Alcohol, drugs, depression, and other co-occurring conditions
Co-occurring substance use should not automatically exclude PTSD care. NICE explicitly advises against exclusion based solely on alcohol or drug misuse. Integrated and coordinated treatment may be preferable when risks or functional difficulties are closely connected. Severe depression that prevents engagement or creates serious harm risk may require more immediate attention; otherwise PTSD treatment itself may also alleviate depressive symptoms. Care sequencing should follow a full assessment rather than a blanket rule.
19. Children and adolescents
For children, trauma-focused cognitive behavioral therapy uses age-appropriate methods and often includes caregivers when appropriate. Pediatric protocols, consent, developmental context, safeguarding, school functioning, and family factors change the reassessment. Under NICE guidance, EMDR can be considered for ages 7–17 when the child has not responded to or engaged with trauma-focused CBT under specified circumstances. Adult medication and psychotherapy findings should not automatically be extended to children. See PTSD in children and teenagers.
20. Ongoing danger and social circumstances
When a person remains exposed to threats or abuse, clinicians should address actual safety, safeguarding, basic resources, and access to care. PTSD treatment can be difficult to engage with while a person is continually managing immediate danger. Housing, financial barriers, displacement, family violence, discrimination, or legal proceedings may influence the choice, timing, and delivery of care. The practical priority is collaborative risk assessment and feasible support rather than assuming all symptoms can be addressed through psychotherapy alone.
X. How to Prepare for a PTSD Treatment Review
Before an appointment, summarize the original treatment goals, what therapy or medication you received, approximate dates, symptom changes, side effects, barriers to attendance, and the biggest remaining problems in daily life. Bring any prior treatment summary or results of validated assessments when available. The purpose is to help the clinician understand your trajectory; an online screening tool cannot settle the diagnosis or determine treatment failure.
Useful questions include: What is our working diagnosis, and what evidence supports it? Which PTSD-specific treatment have I actually received, and have we completed its key components? What changes do my symptom measures and daily functioning show? What other conditions, risks, or practical obstacles should we reassess? What options have the strongest evidence for someone with my prior treatment history? What are the expected benefits, burdens, and adverse effects? When will we review the new plan, and who should I contact if symptoms worsen?
The resulting plan can specify measurable goals, an agreed intervention, anticipated review points, responsibility for monitoring, support between visits, and a safety arrangement where indicated. NICE emphasizes continuity during transitions between services. If a different clinician will take over, coordinate transfer of relevant information with consent.
XI. What Recovery Can Look Like After a Disappointing Treatment Experience
Recovery may involve reduced intrusion and avoidance, better sleep, more flexible responses to reminders, improved relationships, or regained participation in daily life. Symptoms and functioning do not necessarily change at the same rate. A person may need another treatment course, follow-up for residual symptoms, or a separate intervention for depression, sleep, pain, or substance use. Recurrence after improvement can also justify reassessment and renewed care.
A setback does not invalidate previously achieved progress. Equally, hope should rest on clinically realistic goals rather than promises of a fixed recovery schedule. Our articles on whether PTSD can go away and evidence-based PTSD treatment choices explain the broader outlook and treatment evidence. This article's main decision principle remains practical: reassess the situation, identify what has already been tried, and choose the next care step through shared clinical decision-making. For a broader recovery perspective, see our article on trauma recovery and rebuilding safety.
XII. Frequently Asked Questions
21. Why is my PTSD therapy not working?
Possible explanations include an incomplete treatment course, a mismatch between therapy and treatment targets, missed co-occurring conditions, continuing danger, access barriers, adverse effects, or individual variation in treatment response. A careful review is needed to identify which of these actually applies. Evidence-based PTSD treatment is effective on average, but a significant minority of study participants do not achieve a specified response by the end of the first course.
22. How long should I try PTSD therapy before changing?
The appropriate interval depends on the treatment protocol, the amount of active treatment received, early response, safety, tolerability, and preferences. Discuss progress regularly, and request an earlier review whenever deterioration or significant concerns arise. A fixed number of sessions cannot replace individualized evaluation.
23. If CBT did not help, can EMDR or prolonged exposure still help?
Possibly. PTSD interventions differ in their procedures, and one unsuccessful treatment does not establish that other evidence-based therapies will fail. Strong evidence supports several therapies as initial PTSD treatments, while evidence about which precise sequence is optimal after nonresponse is limited. A trained clinician can assess the suitability of another approach.
24. Does worsening during exposure mean I should stop?
Worsening merits assessment, especially if it persists, impairs safety, or makes daily functioning markedly worse. A trained clinician can distinguish expected temporary distress from harmful deterioration, review treatment delivery, and decide whether to adapt, pause, or change the plan. Do not undertake intensive exposure on your own to test whether more distress will help.
25. Can PTSD medication be changed if it does not work?
Yes, a qualified prescriber can evaluate a medication's effect, sufficient trial duration, adverse effects, interactions, and alternatives. Some antidepressants have PTSD-specific evidence; others have uncertain evidence or may be appropriate for separate conditions. Changes require supervision, including safe tapering where indicated.
26. Is treatment-resistant PTSD an official diagnosis?
Treatment-resistant or refractory PTSD is a descriptive research and clinical phrase used for persistent symptoms despite treatment. There is no single universally accepted threshold or separate DSM-5-TR or ICD-11 diagnosis called treatment-resistant PTSD. The label should not be applied simply because someone has attended a few therapy sessions or scored above a questionnaire threshold.
27. What if I have complex PTSD and regular PTSD therapy did not help?
Ask for a reassessment of the symptom profile, emotional regulation, interpersonal difficulties, dissociation, co-occurring conditions, safety, and how the therapy was delivered. Trauma-focused therapies may help people with ICD-11 complex PTSD, while specific modular or phase-based adjustments are sometimes clinically useful. Comparative evidence remains incomplete.
28. Can I improve without talking about traumatic memories in detail?
Some evidence-supported approaches differ in how much detailed verbal recounting they require, and individual preferences are important in treatment choice. A clinician can explain CPT, EMDR, PE, medication, and other supported options. Avoidance of any discussion of trauma may also affect particular treatments, so the decision should be made with a clear understanding of each therapy's actual demands.
29. Should I switch therapists or get a second opinion?
A second opinion can be useful when the diagnosis is unclear, outcomes remain poor, clinical risk is high, or the treatment plan cannot be explained collaboratively. Consider clinician competence in the specific PTSD intervention, communication, accessibility, and arrangements for continuity. Changing therapists and changing treatment modalities are separate decisions.
30. What if PTSD improved but I still have nightmares or depression?
Residual symptoms may require a targeted assessment and an additional evidence-based plan. Persistent nightmares, insomnia, depression, and pain can each have specific treatments. Continuing those symptoms does not automatically mean the entire PTSD therapy failed, and improvements in PTSD severity may coexist with other needs.
Related Articles
References
American Psychological Association. (2025). Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder in Adults.
American Psychological Association. (2025). PTSD Treatments: Recommended and Suggested Interventions.
National Institute for Health and Care Excellence. (2018). Post-traumatic stress disorder: NG116 recommendations.
Semmlinger, V., Leithner, C., Klöck, L. M., Ranftl, L., Ehring, T., & Schreckenbach, M. (2024). Prevalence and predictors of nonresponse to psychological treatment for PTSD: A meta-analysis. Depression and Anxiety, 2024, 9899034.
U.S. Department of Veterans Affairs and U.S. Department of Defense. (2023). VA/DoD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder.
U.S. Department of Veterans Affairs, National Center for PTSD. Choosing a Treatment.
U.S. Department of Veterans Affairs, National Center for PTSD. Clinician-Administered PTSD Scale for DSM-5 (CAPS-5).
U.S. Department of Veterans Affairs, National Center for PTSD. Clinician's Guide to Medications for PTSD.
U.S. Department of Veterans Affairs, National Center for PTSD. Complex PTSD: Assessment and Treatment.
U.S. Department of Veterans Affairs, National Center for PTSD. Complex PTSD: History and Definitions.
U.S. Department of Veterans Affairs, National Center for PTSD. Overview of Psychotherapy for PTSD.
U.S. Department of Veterans Affairs, National Center for PTSD. PTSD Checklist for DSM-5 (PCL-5).
Wright, S., et al. (2024). Predictors of study dropout in cognitive-behavioural therapy with a trauma focus for post-traumatic stress disorder in adults: An individual participant data meta-analysis. BMJ Mental Health, 27, e301159.